Halozyme Therapeutics (HALO) Tops Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $108.31 --0%
Revenue Growth %: +36.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SUNB, CULP, KFY, More
Revenue Growth %: +36.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.21), $0.07 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $39 million versus the consensus estimate of $38.37 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Core & Main, Inc (CNM) Tops Q3 EPS by 2c ; Offers Guidance
- Sysco raises mid-term targets, unveils $500M AI efficiency program
- J.Jill (JILL) Tops Q2 EPS by 67c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
